Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
The broader economic benefits of COVID-19 vaccination
13 October 2025
Extending COVID-19 vaccination eligibility to working-age adults could nearly triple the benefits to national economies.
Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape
24 September 2025
Saudi Arabia’s healthcare system is undergoing major transformation under Vision 2030, reshaping regulation, funding and delivery models across the Kingdom. The introduction of a formal health technology assessment (HTA) framework and evolving reimbursement pathways are central to improving access to value-based healthcare.
Around the world in HTAs: China – From fragmentation to function
2 September 2025
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition Yawen Jiang, Meng Li and Claud Theakston take us to China.
How Widely Are QALYs Used in OECD Countries? A Snapshot of International Practices
11 June 2025
As healthcare systems strive to allocate resources efficiently, the use of economic evaluation metrics like Quality-Adjusted Life Years (QALYs) has become increasingly important.
Around the World in HTAs: Kenya – Riding the Waves of Change
19 May 2025
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Angela Kairu and Edwine Barasa of the KEMRI Wellcome Trust Research Programme, and Paul Oyalo of OHE, take us to Kenya.
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
Long-acting (LA) therapies represent a significant innovation in pharmaceutical development by offering a sustained drug effect with reduced administration frequency.
An Analysis of NICE’s Optimised Decisions from 2015 to 2024
1 May 2025
The National Institute for Health and Care Excellence (NICE) is the body responsible for recommending medicines for use within the National Health Service (NHS) in England.
The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region
14 April 2025
Health Technology Assessment (HTA) agencies evaluate and make decisions on the use, funding, or reimbursement of health technologies based on clinical and economic evidence.
Around the World in HTAs: Canada – Autonomous yet Collaborative
9 April 2025
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Adam Raymakers and Chris Skedgel take us to Canada.